The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Timeframe: Baseline
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Timeframe: Week 4
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Timeframe: Week 10
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Timeframe: Week 14
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Timeframe: Week 22